105 related articles for article (PubMed ID: 19594486)
1. Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines.
Laine L; Connors L; Griffin MR; Curtis SP; Kaur A; Cannon CP
Aliment Pharmacol Ther; 2009 Oct; 30(7):767-74. PubMed ID: 19594486
[TBL] [Abstract][Full Text] [Related]
2. Rheumatologists' adherence to guidelines for misoprostol use in patients at high risk for nonsteroidal antiinflammatory drug gastropathy.
Cibere J; Sibley JT; Haga M
J Rheumatol; 2002 Feb; 29(2):339-46. PubMed ID: 11838854
[TBL] [Abstract][Full Text] [Related]
3. Underutilization of preventive strategies in patients receiving NSAIDs.
Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
[TBL] [Abstract][Full Text] [Related]
4. Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population.
Rahme E; Pettitt D; LeLorier J
Arthritis Rheum; 2002 Nov; 46(11):3046-54. PubMed ID: 12428249
[TBL] [Abstract][Full Text] [Related]
5. GI risk factors and use of GI protective agents among patients receiving nonsteroidal antiinflammatory drugs.
Harris CL; Raisch DW; Abhyankar U; Marfatia S; Campbell HM; Sather MR
Ann Pharmacother; 2006 Nov; 40(11):1924-31. PubMed ID: 17047140
[TBL] [Abstract][Full Text] [Related]
6. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications.
Goldstein JL; Howard KB; Walton SM; McLaughlin TP; Kruzikas DT
Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1337-45. PubMed ID: 17088110
[TBL] [Abstract][Full Text] [Related]
7. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs.
Abraham NS; El-Serag HB; Johnson ML; Hartman C; Richardson P; Ray WA; Smalley W
Gastroenterology; 2005 Oct; 129(4):1171-8. PubMed ID: 16230071
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial.
Simon LS; Hatoum HT; Bittman RM; Archambault WT; Polisson RP
Fam Med; 1996 Mar; 28(3):204-10. PubMed ID: 8900554
[TBL] [Abstract][Full Text] [Related]
9. Co-prescribing of proton pump inhibitors among chronic users of NSAIDs in the UK.
Suh DC; Hunsche E; Shin HC; Mavros P
Rheumatology (Oxford); 2008 Apr; 47(4):458-63. PubMed ID: 18263598
[TBL] [Abstract][Full Text] [Related]
10. Appropriateness of NSAID and Coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: results from the CANOAR study.
Sebaldt RJ; Petrie A; Goldsmith CH; Marentette MA
Am J Manag Care; 2004 Nov; 10(11 Pt 1):742-50. PubMed ID: 15623264
[TBL] [Abstract][Full Text] [Related]
11. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
Targownik LE; Metge CJ; Leung S; Chateau DG
Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634
[TBL] [Abstract][Full Text] [Related]
12. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
[TBL] [Abstract][Full Text] [Related]
13. Use of gastrointestinal preventive therapy among elderly persons receiving antiarthritic agents in Nova Scotia, Canada.
Hartnell NR; Flanagan PS; MacKinnon NJ; Bakowsky VS
Am J Geriatr Pharmacother; 2004 Sep; 2(3):171-80. PubMed ID: 15561649
[TBL] [Abstract][Full Text] [Related]
14. Long-term NSAID use in primary care: changes over a decade and NICE risk factors for gastrointestinal adverse events.
Thompson PW; Tee L; McBride J; Quincey D; Strat Liddiard G
Rheumatology (Oxford); 2005 Oct; 44(10):1308-10. PubMed ID: 15972345
[TBL] [Abstract][Full Text] [Related]
15. Use of gastroprotection in patients discharged from hospital on nonsteroidal anti-inflammatory drugs.
Coté GA; Norvell JP; Rice JP; Bulsiewicz WJ; Howden CW
Am J Ther; 2008; 15(5):444-9. PubMed ID: 18806520
[TBL] [Abstract][Full Text] [Related]
16. Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals.
Greenberg JD; Bingham CO; Abramson SB; Reed G; Kishimoto M; Hinkle K; Kremer J
Arthritis Rheum; 2006 Aug; 55(4):543-50. PubMed ID: 16874798
[TBL] [Abstract][Full Text] [Related]
17. Use of physician education and computer alert to improve targeted use of gastroprotection among NSAID users.
Coté GA; Rice JP; Bulsiewicz W; Norvell JP; Christensen K; Bobb A; Postelnick M; Howden CW
Am J Gastroenterol; 2008 May; 103(5):1097-103. PubMed ID: 18477341
[TBL] [Abstract][Full Text] [Related]
18. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage.
van Soest EM; Sturkenboom MC; Dieleman JP; Verhamme KM; Siersema PD; Kuipers EJ
Aliment Pharmacol Ther; 2007 Jul; 26(2):265-75. PubMed ID: 17593072
[TBL] [Abstract][Full Text] [Related]
19. NSAIDs-induced gastrointestinal damage. Review.
Arroyo M; Lanas A
Minerva Gastroenterol Dietol; 2006 Sep; 52(3):249-59. PubMed ID: 16971869
[TBL] [Abstract][Full Text] [Related]
20. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
Rostom A; Moayyedi P; Hunt R;
Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]